Investor Presentation H1 2023

114 Investor presentation First six months of 2023 Growth momentum has increased driven by demographics and utilisation of full product portfolio International Operations is diverse and covers 190 markets Historic growth has been in the range of 5-10% Growth momentum in IO Novo NordiskⓇ 27% 20% 15% 9% >487m 16% 30% live with diabetes 16 12 >600m live with obesity 8 5% IO's share of revenue FY 2022 4 اااس 10% 0 0% 2015 2022 May 2020 NAO 51% 49% ΙΟ Growth rate range NAO: North America Operations; IO: International Operations; Share of Growth not depicted due to high numbers; FY: Full Year Source (RHS): IQVIA May 2023, Value, MAT NN Diabetes market share -Market growth NN Diabetes growth May 2023

View entire presentation